Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseHematopoietic Stem CellsTransplantation ConditioningHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsBone Marrow CellsGraft vs Leukemia EffectWhole-Body IrradiationPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaHistocompatibilityTreatment OutcomeHistocompatibility TestingGraft SurvivalStem CellsRecurrenceMyeloablative AgonistsGraft vs Tumor EffectChimerismRetrospective StudiesHematologic DiseasesLeukemia, Myeloid, AcuteAnemia, AplasticMyelodysplastic SyndromesCord Blood Stem Cell TransplantationHematopoiesisImmunosuppressive AgentsVidarabineRemission InductionLymphocyte TransfusionHLA AntigensHepatic Veno-Occlusive DiseaseAllograftsPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation, IsogeneicLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsLiver TransplantationCombined Modality TherapyTime FactorsTransplantation ImmunologySurvival RateCytomegalovirus InfectionsSurvival AnalysisAcute DiseaseCyclophosphamideMice, Inbred C57BLT-LymphocytesLymphocyte DepletionHematopoietic Stem Cell MobilizationAntigens, CD34Severe Combined ImmunodeficiencyDisease-Free SurvivalFlow CytometryOpportunistic InfectionsMultiple MyelomaFollow-Up StudiesCystitisCell DifferentiationMinor Histocompatibility AntigensLeukemia, MyeloidLeukemic InfiltrationImmunosuppressionAntilymphocyte SerumNeoplasm, ResidualSalvage TherapyLymphoproliferative DisordersKidney TransplantationColony-Forming Units AssayGraft RejectionBone and BonesCell LineageAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusImmunocompromised HostPrognosisBlood Group IncompatibilityFatal OutcomeBronchiolitis ObliteransRisk FactorsBone Marrow PurgingCyclosporineFetal BloodCytarabineMesenchymal Stem Cell TransplantationCell TransplantationCells, CulturedRadiation ChimeraGranulocyte Colony-Stimulating FactorMelphalanMycosesPrimary Myelofibrosis